Announcements Trials
Browse Landscape

Phase

Phase 3 1Phase 2 1

Status

Active not recruiting 2

Sponsor Class

INDUSTRY 2

Study Type

Interventional 2

Sponsor

Cancer Type

Genitourinary 2

Conditions

Ovarian Neoplasms 11Prostatic Neoplasms 7Fallopian Tube Neoplasms 5Neoplasms 3Breast Neoplasms 3Prostatic Neoplasms, Castration-Resistant 2Neoplasm Metastasis 2Glioblastoma 2Carcinoma, Ovarian Epithelial 2Triple Negative Breast Neoplasms 1Small Cell Lung Carcinoma 1Prostate Adenocarcinoma 1Pathologic Complete Response 1Pancreatic Neoplasms 1Metastatic Hormone-sensitive Prostate Cancer (mHSPC) 1Metastatic Castration-sensitive Prostate Cancer 1Lung Neoplasms 1Hemangiosarcoma 1Head and Neck Neoplasms 1Glioma 1Endometrial Neoplasms 1Disease Progression 1Carcinoma, Non-Small-Cell Lung 1Carcinoma, Neuroendocrine 1Brain Neoplasms 1Biliary Tract Neoplasms 1

Interventions

Prednisone 5Docetaxel 4niraparib 2enzalutamide 2darolutamide 2Pluvicto 2Abiraterone Acetate 2olaparib 1ibrutinib 1gedatolisib 1gallium 68 PSMA-11 1fludrocortisone acetate 1cabazitaxel 1abiraterone 1Rosuvastatin Calcium 1Pioglitazone 1Omeprazole 1JNJ-64619178 1JNJ-64264681 1Dexamethasone 1(225)Ac-PSMA-617 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Prostatic Neoplasms, Castration-Resistant × niraparib × 90 days × Clear all
NCT03431350 2026-05-11

QUEST

Janssen Research & Development, LLC

Phase 2 Active not recruiting
136 enrolled 29 charts
Genitourinary

Prostatic Neoplasms, Castration-Resistant

NCT03748641 2026-05-08

MAGNITUDE

Janssen Research & Development, LLC

Phase 3 Active not recruiting
765 enrolled 16 charts 1 FDA
Genitourinary

Prostatic Neoplasms, Castration-Resistant

Data powered by HemOnc (CC BY 4.0) Colophon âš¡